Urolithin A

Mechanism of Action

Urolithin A operates through several interconnected molecular pathways, with mitophagy activation being a central mechanism. Based on the available evidence, here's how it works:

Mitophagy Activation
Urolithin A activates mitophagy (the selective removal of damaged mitochondria) via the AMPK-mTOR signaling axis. This process helps maintain mitochondrial quality control, which is crucial for cellular energy production and overall cellular health. In cardiac tissue, this mechanism appears to help ameliorate cardiac remodeling associated with heart failure with preserved ejection fraction (HFpEF).

Antioxidant Signaling
The compound suppresses ferroptosis (a form of programmed cell death driven by iron-dependent lipid peroxidation) through activation of the Nrf2 signaling pathway. This antioxidant mechanism has been demonstrated in hippocampal tissue, where it may protect against cognitive impairments and anxiety associated with chronic sleep deprivation.

Metabolic Modulation
Urolithin A promotes fatty acid oxidation by orchestrating β-Catenin signaling pathways. This metabolic effect has been shown to help mitigate renal fibrosis, suggesting the compound can influence tissue remodeling processes through metabolic reprogramming.

Gut-Related Effects
The compound modulates the gut-ceramide axis, which may contribute to its protective effects against gut barrier dysfunction. This mechanism appears relevant for protecting against environmental toxin-induced intestinal damage.

Limitations of Current Evidence
While these mechanisms are supported by preclinical studies, the evidence base is still developing. Most mechanistic data comes from animal studies, and the clinical significance of these pathways in humans requires further validation through ongoing and future clinical trials.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation.

Urolithin A is being investigated for several clinical applications, though the available evidence is still emerging. Based on current research, the primary areas of clinical interest include:

Muscle Health and Performance

Clinical trials have examined urolithin A's effects on skeletal muscle function and endurance performance (NCT04783207), as well as its potential to mitigate muscle loss during periods of immobilization when combined with protein supplementation (NCT05814705). These studies reflect interest in urolithin A's proposed ability to enhance mitochondrial function in muscle tissue.

Metabolic Health and Obesity

A completed clinical trial investigated urolithin A supplementation specifically in middle-aged adults with obesity (NCT05921266), suggesting potential applications for metabolic health management. Additionally, research has examined effects on lipid metabolism, with one study in postmenopausal women showing that polyphenol compounds (which can generate urolithin A) may improve LDL particle quality despite increasing circulating lipids.

Immune Function

Clinical research has explored urolithin A's potential to boost immune health (NCT05735886), though specific outcomes from this completed trial are not detailed in the available evidence.

Cardiovascular Applications

Preclinical research suggests potential applications for heart failure with preserved ejection fraction (HFpEF), where urolithin A appeared to improve cardiac remodeling through mitochondrial pathways. However, clinical validation of cardiovascular benefits in humans remains to be established.

Emerging Applications

Early-stage research is investigating urolithin A in the context of alcohol use disorder and alcohol-related liver disease (NCT07678567), though this trial has not yet begun recruiting participants.

Clinical Evidence Limitations: While multiple clinical trials have been completed, detailed results and efficacy data are not available in the current evidence base. Most mechanistic understanding comes from preclinical studies, and robust clinical data demonstrating therapeutic efficacy for specific conditions remains limited.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation regimen.

The safety evidence for urolithin A supplementation is currently very limited, with most available data coming from animal studies rather than comprehensive human clinical trials.

Known Side Effects

Evidence is extremely thin regarding documented side effects in humans. The clinical trials listed (NCT04783207, NCT05921266, NCT05735886) have been completed but their safety results are not provided in the available evidence. Without access to these trial outcomes, specific side effect profiles cannot be established.

Contraindications and Populations That Should Avoid It

No established contraindications are documented in the provided evidence. However, this absence likely reflects limited safety data rather than confirmed safety across all populations.

Drug Interactions

No drug interaction data is available in the provided evidence. Given that some preclinical studies suggest urolithin A affects cellular pathways like AMPK-mTOR signaling and β-catenin pathways, potential interactions with medications targeting these systems cannot be ruled out, but no specific interactions have been documented.

Special Populations

The provided evidence includes one study in postmenopausal women examining polyphenol effects (which may include urolithin A precursors), but no specific safety data for pregnant women, nursing mothers, children, or individuals with chronic medical conditions is available.

Critical Evidence Gap

The safety profile of urolithin A remains poorly characterized in humans. While several clinical trials have been completed, their safety outcomes are not included in the available evidence. Most research has focused on efficacy endpoints in animal models rather than comprehensive human safety assessment.

---

This information is for educational purposes only and does not constitute medical advice. Consult with a healthcare provider before using urolithin A supplements, especially given the limited human safety data currently available.

Research Papers and Clinical Trials

Current research on Urolithin A spans multiple therapeutic areas, with studies investigating its effects on cellular health, metabolic function, and age-related conditions.

Preclinical Research

Several recent animal studies have explored Urolithin A's therapeutic potential across different organ systems. A 2026 study in Experimental & Molecular Medicine examined Urolithin A's effects on heart failure with preserved ejection fraction (HFpEF), finding that it activates mitophagy (cellular cleanup of damaged mitochondria) through the AMPK-mTOR pathway while modulating gut-ceramide interactions to improve cardiac remodeling. Another 2026 study in Gut Microbes investigated Urolithin A's protective effects against arsenic-induced gut barrier dysfunction using humanized mice models.

Research has also focused on kidney health, with a 2026 FASEB Journal study showing that Urolithin A may reduce renal fibrosis by promoting fatty acid oxidation through β-catenin signaling. In the area of cognitive health, a 2026 Phytomedicine study found that Urolithin A supplementation improved sleep deprivation-induced cognitive impairments and anxiety in mice by reducing hippocampal ferroptosis (a form of cell death) via Nrf2 signaling pathways.

Human Clinical Trials

Multiple clinical trials are investigating Urolithin A's effects in humans, though specific sample sizes and detailed results are not provided in the available evidence. Completed studies include trials examining its effects on skeletal muscle function, iron metabolism, and endurance performance (NCT04783207), as well as studies in middle-aged adults with obesity (NCT05921266) and immune health applications (NCT05735886).

An active trial is investigating protein supplementation with or without Urolithin A during single-leg immobilization (NCT05814705), while the PROMETHEUS clinical trial protocol outlines plans to study lifestyle and nutraceutical interventions for healthy aging, potentially including Urolithin A.

Research Limitations

While these studies suggest promising therapeutic potential, the evidence base remains limited. Most mechanistic research comes from animal models, and human clinical trial results are not yet widely published. The translation of preclinical findings to human health benefits requires further investigation through well-designed clinical studies.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation.

Dosing and Administration Protocols

Based on available clinical trial evidence, urolithin A has been investigated at various doses in human studies, though specific dosing details are limited in the provided abstracts.

Reported Dosing Regimens

The completed clinical trials (NCT04783207, NCT05921266, NCT05735886) examining urolithin A supplementation in humans have investigated its effects on skeletal muscle function, obesity-related outcomes, and immune health, but specific dosing protocols are not detailed in the available trial summaries.

One ongoing study (NCT05814705) is examining protein supplementation with or without urolithin A during muscle immobilization, though the urolithin A dose is not specified in the available information.

Formulation and Product Information

Some studies reference "Mitopure," which appears to be a standardized urolithin A supplement formulation, though specific concentration and dosing recommendations are not provided in the available evidence.

Evidence Limitations

The current literature provides limited detailed information about optimal dosing protocols for urolithin A supplementation. Most available studies focus on mechanistic effects rather than dose-response relationships or standardized administration guidelines. The ongoing PROMETHEUS clinical trial (PMID: 42393428) may provide additional protocol information as results become available.

---

Important Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Dosing and administration of any supplement should be determined in consultation with a qualified healthcare provider who can assess individual health status, potential interactions, and appropriate monitoring protocols.

Outcomes

The evidence for measurable outcomes with Urolithin A is predominantly from preclinical studies, with limited human clinical data currently available.

Preclinical Outcomes

Cardiovascular Effects:
Animal studies report improvements in cardiac remodeling in heart failure with preserved ejection fraction (HFpEF), with Urolithin A appearing to activate mitophagy through the AMPK-mTOR pathway. However, specific quantitative outcomes are not detailed in the available evidence.

Renal Function:
Preclinical research suggests Urolithin A may reduce renal fibrosis by promoting fatty acid oxidation through β-Catenin signaling modulation, though specific biomarker changes or functional measurements are not provided in the current evidence.

Cognitive and Neurological Outcomes:
Mouse studies indicate potential benefits for sleep deprivation-induced cognitive impairments and anxiety, reportedly through suppression of hippocampal ferroptosis via Nrf2 signaling. Specific cognitive assessment scores or anxiety measurements are not detailed.

Gastrointestinal Effects:
Animal research suggests protective effects against gut barrier dysfunction in arsenic exposure models, though quantitative barrier function measurements are not specified in the available evidence.

Human Clinical Outcomes

Lipid Profile Effects:
One randomized, placebo-controlled crossover trial in postmenopausal women found that polyphenols (including compounds that produce Urolithin A) increased circulating lipids but improved LDL particle quality and reduced LDL oxidation. However, this study examined polyphenols broadly rather than isolated Urolithin A.

Clinical Trial Status:
Multiple human trials examining Urolithin A's effects on skeletal muscle function, immune health, and metabolic parameters have been completed, but specific outcome data from these studies is not provided in the current evidence base.

Evidence Limitations

The strength of evidence remains limited for human outcomes. While several clinical trials have been completed investigating effects on muscle function, immune health, and obesity-related parameters, the specific measurable results from these studies are not available in the current literature summary. Most detailed mechanistic and outcome data comes from animal studies, which may not directly translate to human clinical benefits.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation.